Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

What are the top COVID-19 vaccine candidates?

September 25, 2020 By Nancy Crotti

Moderna

Scientists began Phase 1 trials of the first experimental vaccine for COVID-19 in mid-March. The vaccine, called mRNA-1273, is being co-developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) and the Cambridge, Mass.-based biotech company Moderna (NSDQ:MRNA). Forty-eight healthy adults ages 18 to 55 were divided into three groups, each of which received different doses of the vaccine — 25, 100, or 250 µg. Participants received two injections, 28 days apart.

The two-dose vaccine is designed to prompt the immune system to produce antibodies against a portion of the coronavirus “spike” protein, which the virus uses to bind to and enter human cells. The vaccine uses messenger RNA (mRNA), a molecule critical for the virus to produce protein, according to the National Institutes of Health (NIH).

A larger Phase 2 clinical trial began in late May, followed by the Phase 3 trial, which launched in July with a goal of enrolling 30,000 adults. Moderna is conducting the Phase 3 trial in conjunction with NIAID and the Biomedical Advanced Research and Development Authority (BARDA). The primary endpoint will be the prevention of symptomatic COVID-19, with key secondary endpoints including prevention of severe COVID-19 (defined by the need for hospitalization) and prevention of infection by SARS-CoV-2 (the virus causing COVID-19) regardless of symptomology. Primary efficacy analysis will be based on the number of participants with symptomatic COVID-19 disease, according to NIH.

As of September 18, the Phase 3 trial had enrolled 25,976 participants and 11,879 had received their second vaccination. Moderna and competitor Pfizer took the unusual step of making their Phase 3 study protocols public before the study was completed, possibly due to the political pressure to produce a COVID-19 vaccine before the November 2020 election. Moderna’s protocol may be found here. Other companies have since followed suit.

Moderna is also collaborating with PPD for drug development, laboratory and lifecycle management services, while the company last month announced a collaboration for large-scale, commercial fill-finish manufacturing of its vaccine candidate with Catalent (NYSE:CTLT). Moderna said in July that it remains on track to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021.

Next>>

Pages: 1 2 3 4 5 6 7

Related Articles Read More >

A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies
FDA
FDA issues draft guidance for increasing racial and ethnic diversity in clinical trials
Symplicity Spyral renal denervation system Medtronic
Medtronic releases new renal denervation results, closes trial enrollment

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech